NDAORALTABLET
Lifecycle
Pre-Launch
Clinical Trials
20
Data completeness
3/8 — Basic
NEVIRAPINE TABLETS FOR ORAL SUSPENSION (nevirapine) by Aurobindo Pharma is non-nucleoside reverse transcriptase inhibitors [moa]. Approved for hiv infection, acquired immunodeficiency syndrome, hepatic insufficiency and 2 more indications.
Drug data last refreshed 2w ago
Mechanism of Action
Non-Nucleoside Reverse Transcriptase Inhibitors
Worked on NEVIRAPINE TABLETS FOR ORAL SUSPENSION at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.